Partnering Opportunities

OUT-LICENSING OPPORTUNITIES – Protox is evaluating potential partners to either co-develop or out-license the development and commercialization of PRX302 for prostate cancer and benign prostatic hyperplasia (BPH) programs. Potential partners must have the commercial infrastructure and resources necessary to effectively develop and promote PRX302 for these significant markets.

IN-LICENSING AND COLLABORATION OPPORTUNITIES – In order to leverage the company’s core expertise in targeted toxin-based therapeutics, Protox is actively seeking partnerships focusing on the discovery and development of immunotoxins or fusion proteins that combine the specificity of receptor targeted antibodies or ligands with the selective proteolytic activation of PORxin™ drug candidates. We believe that such dual targeting will offer an improved therapeutic window compared to either approach alone.

If you are interested in exploring either of these opportunities, please contact

Shafique Fidai,
Senior Director, Corporate Development
business@protoxtherapeutics.com